Kirin and Suntory call off merger talks
This article was originally published in Scrip
Kirin and Suntory have decided to call off discussions aimed at a merger of the two companies, citing a number of irreconcilable differences over fundamental issues.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.